Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | PARP1 | P09874 | 1/20 | 0.60 |
| ▸ | APAF1 | O14727 | 6/20 | 0.54 |
| ▸ | CASP3 | P42574 | 6/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 6/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 6/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 5/20 | 0.54 |
| ▸ | CASP6 | P55212 | 4/20 | 0.54 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 10/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | SAE1 | Q9UBE0 | 4/20 | 0.49 |
| ▸ | UBA2 | Q9UBT2 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | UBE2I | P63279 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7343701 | 0.82 | LOXL2 (0.60) | LOXL2KDM4EGAAPARP1APAF1 | |
| SCHEMBL24459973 | 0.82 | LOXL2 (0.47) | LOXL2KDM4EGAAPARP1APAF1 | |
| SCHEMBL2532412 | 0.81 | PARP1 (0.65) | LOXL2KDM4EGAAPARP1APAF1 | |
| SCHEMBL15303909 | 0.81 | LOXL2 (1.00) | LOXL2KDM4EGAAPARP1APAF1 | |
| SCHEMBL7452968 | 0.81 | LOXL2 (0.68) | LOXL2KDM4EGAAPARP1APAF1 | |
| SCHEMBL6046763 | 0.81 | LOXL2 (0.68) | LOXL2KDM4EGAAPARP1APAF1 | |
| SCHEMBL30249827 | 0.81 | LOXL2 (1.00) | LOXL2KDM4EGAAPARP1APAF1 | |
| SCHEMBL6645515 | 0.80 | TNKS (0.62) | LOXL2KDM4EGAAPARP1APAF1 | |
| SCHEMBL1719557 | 0.79 | PARP1 (0.46) | LOXL2KDM4EGAAPARP1TNKS2 | |
| SCHEMBL1720887 | 0.79 | PARP1 (0.46) | LOXL2KDM4EGAAPARP1APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
| EP-1284967-A1 | 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES | Celltech R&D Limited (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-6403608-B1 | ANTIINFLAMMATORY AND IMMUNE DISORDERS | CELLTECH R&D, LTD. (GB) | 2002-06-11 | — | — | US | disclosed |
| WO-2001092233-A1 | 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2001-12-06 | — | — | WO | disclosed |
| US-5407942-A | For treating hypertension, atherosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1995-04-18 | — | — | US | disclosed |
| EP-0569795-B1 | Sulphonylbenzyl substituted benzo- and pyridopyridones | BAYER AG (DE) | 1995-04-12 | — | — | EP | disclosed |
| US-5354749-A | For treating arterial hypertension and atheroschlerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1994-10-11 | — | — | US | disclosed |
| EP-0569794-A1 | Biphenylmethyl-substituted pyridones useful as angiotensin II receptor antagonists. | BAYER AG (DE) | 1993-11-18 | — | — | EP | disclosed |
| EP-0569795-A1 | Sulphonylbenzyl substituted benzo- and pyridopyridones | BAYER AG (DE) | 1993-11-18 | — | — | EP | disclosed |
| WO-1993014086-A1 | SUBSTITUTED 1-ISOQUINOLONE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1993-07-22 | — | — | WO | disclosed |
| US-3961062-A | Pharmaceutical composition containing 1-(imidazole-1-yl)-isoquinolines and method of treating hyperlipemia | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | LOXL2 4474/4885KDM4E 3585/4885GAA 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.